Quick Answer
ZyVersa Therapeutics, Inc. reported Net Income of -$24.95 million for fiscal year 2025.
ZyVersa Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$24.95M -165.1% |
-$9.41M +90.4% |
-$98.30M -599.7% |
-$14.05M | — |
| Diluted EPS | -$4.18 +50.7% |
-$8.48 +99.2% |
-$1089.70 -109970.7% |
-$0.99 | — |
| Total Assets | $347.9K -98.3% |
$20.60M -6.9% |
$22.11M -81.3% |
$118.51M +53.6% |
$77.14M |
| Cash and Equivalents | — | — | — | — | $928.4K |
| Stockholders Equity | -$12.39M -245.4% |
$8.52M -23.1% |
$11.07M -88.9% |
$99.68M +4513.7% |
-$2.26M |
| R&D Expense | $1.11M -37.4% |
$1.78M -44.5% |
$3.21M -40.7% |
$5.41M | — |
| Operating Income | -$25.49M -179.0% |
-$9.14M +91.5% |
-$107.75M -728.0% |
-$13.01M | — |
| Shares Outstanding | 8.10M +222.8% |
2.51M +523.6% |
402,205 +56.1% |
257,604 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$19.81M | -724.8% | -795.6% |
| Diluted EPS | September 30, 2025 | -$2.56 | -5.3% | -456.5% |
| Total Assets | September 30, 2025 | $1.04M | -94.6% | -94.7% |
| Cash and Equivalents | September 30, 2022 | $213.6K | — | -37.2% |
| Stockholders Equity | September 30, 2025 | -$11.73M | -266.9% | -292.2% |
| R&D Expense | September 30, 2025 | $365.1K | -16.3% | -10.9% |
| Operating Income | September 30, 2025 | -$20.75M | -814.3% | -915.2% |
| Shares Outstanding | September 30, 2025 | 8.10M | +653.7% | +66.1% |
- ZyVersa Therapeutics, Inc. reported Net Income of -$24.95 million for fiscal year 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -165.1% in Net Income compared to the prior fiscal year.
- ZyVersa Therapeutics, Inc. reported Diluted EPS of $4.18 per share (loss) for fiscal year 2025.
- ZyVersa Therapeutics, Inc. showed an increase of +50.7% in Diluted EPS compared to the prior fiscal year.
- ZyVersa Therapeutics, Inc. reported Total Assets of $347.9 thousand for fiscal year 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -98.3% in Total Assets compared to the prior fiscal year.
- ZyVersa Therapeutics, Inc. reported Cash and Equivalents of $928.4 thousand for fiscal year 2021.
- ZyVersa Therapeutics, Inc. reported Stockholders Equity of -$12.39 million for fiscal year 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -245.4% in Stockholders Equity compared to the prior fiscal year.
- ZyVersa Therapeutics, Inc. reported R&D Expense of $1.11 million for fiscal year 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -37.4% in R&D Expense compared to the prior fiscal year.
- ZyVersa Therapeutics, Inc. reported Operating Income of -$25.49 million for fiscal year 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -179.0% in Operating Income compared to the prior fiscal year.
- ZyVersa Therapeutics, Inc. reported Shares Outstanding of 8.10 million shares for fiscal year 2025.
- ZyVersa Therapeutics, Inc. showed an increase of +222.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: